Hutchison China MediTech Umsatz Q / Q
Was ist das Umsatz Q / Q von Hutchison China MediTech?
Umsatz Q / Q von Hutchison China MediTech Ltd. ist -42.64%
Was ist die Definition von Umsatz Q / Q?
Das vierteljährliche Umsatzwachstum im Vergleich zum Vorjahr ist die Steigerung des Umsatzes eines Unternehmens im Vergleich zur Leistung des entsprechenden Quartals eines Vorjahres, ausgedrückt in Prozent.
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
Umsatz Q / Q von Unternehmen in Health Care Sektor auf LSE im Vergleich zu Hutchison China MediTech
Was macht Hutchison China MediTech?
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Unternehmen mit umsatz q / q ähnlich Hutchison China MediTech
- Venzee Technologies hat Umsatz Q / Q von -42.73%
- Stereotaxis hat Umsatz Q / Q von -42.72%
- Riba Textiles hat Umsatz Q / Q von -42.69%
- Bega Cheese hat Umsatz Q / Q von -42.68%
- Nagreeka Exports hat Umsatz Q / Q von -42.67%
- Bowl America hat Umsatz Q / Q von -42.67%
- Hutchison China MediTech hat Umsatz Q / Q von -42.64%
- Startek hat Umsatz Q / Q von -42.61%
- Integrated Diagnostics plc hat Umsatz Q / Q von -42.57%
- iSentric hat Umsatz Q / Q von -42.50%
- Skyline hat Umsatz Q / Q von -42.50%
- 51 Credit Card hat Umsatz Q / Q von -42.44%
- Broo hat Umsatz Q / Q von -42.42%